Design, Synthesis and Biological Evaluation of Pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione Derivatives as Novel Neuroprotective Agents

Jishun Quan , Dongping Zhang , Zhuo Zhang , Jian Wang , Chao Ma , Maosheng Cheng

Chemical Research in Chinese Universities ›› 2021, Vol. 37 ›› Issue (3) : 647 -654.

PDF
Chemical Research in Chinese Universities ›› 2021, Vol. 37 ›› Issue (3) : 647 -654. DOI: 10.1007/s40242-020-0283-z
Article

Design, Synthesis and Biological Evaluation of Pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione Derivatives as Novel Neuroprotective Agents

Author information +
History +
PDF

Abstract

A series of pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione derivatives was designed and synthesized, and their neuroprotective activity against SH-SY5Y cell injury induced by N-methyl-D-aspartic acid(NMDA) was evaluated. All the compounds showed significant neuroprotective effects, especially B16, which showed excellent performance and better activity than the positive control ifenprodil(B16: 56.2%±0.6%; ifenprodil: 41.0%±2.7%). Further investigation indicated that B16 could attenuate the Ca2+ influx induced by NMDA in SH-SY5Y cells and Western blotting also showed that B16 could attenuate the NR2B upregulation in SH-SY5Y cells induced by NMDA. The molecular docking results showed that compound B16 fitted in the binding pocket of NR2B-NMDAR well and could interact with binding sites of compounds 1 and 2 simultaneously. The ADME/Tox prediction results suggested that compound B16 had good blood-brain barrier(BBB) permeability and the zero alert of Pan Assay Interference Structures(PAINS) indicated that B16 could not elicit false-positive activities. These results strongly suggest that B16 is a promising and effective candidate neuroprotective compound, and that NR2B-NMDAR is a potential target of B16.

Keywords

Neuroprotective activity / Ca2+ influx / Western blotting / NR2B-NMDA receptor / Molecular docking

Cite this article

Download citation ▾
Jishun Quan, Dongping Zhang, Zhuo Zhang, Jian Wang, Chao Ma, Maosheng Cheng. Design, Synthesis and Biological Evaluation of Pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione Derivatives as Novel Neuroprotective Agents. Chemical Research in Chinese Universities, 2021, 37(3): 647-654 DOI:10.1007/s40242-020-0283-z

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Buemi M R, De Luca L, Ferro S, Russo E, De Sarro G, Gitto R. Bioorg. Med. Chem., 201, 24: 1513.

[2]

Dey S, Schepmann D, Wunsch B. Bioorg. Med. Chem. Lett., 201, 26: 889.

[3]

Gitto R, De Luca L, Ferro S, Buemi M R, Russo E, De Sarro G, Costa L, Ciranna L, Prezzavento O, Arena E, Ronsisvalle S, Bruno G, Chimirri A. J. Med. Chem., 2011, 54: 8702.

[4]

Parsons C G, Danysz W, Quack G. Drug News Perspect, 1998, 11: 523.

[5]

Tewes B, Frehland B, Schepmann D, Schmidtke K U, Winckler T, Wunsch B. Bioorg. Med. Chem., 2010, 18: 8005.

[6]

Cadinu D, Grayson B, Podda G, Harte M K, Doostdar N, Neill J C. Neuropharmacology, 2018, 142: 41.

[7]

Potschka H, Loscher W, Wlaz P, Behl B, Hofmann H P, Treiber H J, Szabo L. Br. J. Pharmacol., 1998, 125: 1258.

[8]

Glynn-Servedio B E, Ranola T S. Consult Pharm., 2017, 32: 511.

[9]

Shi T, Hao J X, Wiesenfeld-Hallin Z, Xu X J. Scand. J. Pain., 2018, 18: 687.

[10]

Milnerwood A J, Gladding C M, Pouladi M A, Kaufman A M, Hines R M, Boyd J D, Ko R W, Vasuta O C, Graham R K, Hayden M R, Murphy T H, Raymond L A. Neuron, 2010, 65: 178.

[11]

Krausova B, Slavikova B, Nekardova M, Hubalkova P, Vyklicky V, Chodounska H, Vyklicky L, Kudova E. Journal of Medicinal Chemistry, 2018, 61: 4505.

[12]

von Engelhardt J, Coserea I, Pawlak V, Fuchs E C, Kohr G, Seeburg P H, Monyer H. Neuropharmacology, 2007, 53: 10.

[13]

Loftis J M, Janowsky A. Pharmacol. Ther., 2003, 97: 55.

[14]

Furukawa H, Singh S K, Mancusso R, Gouaux E. Nature, 2005, 438: 185.

[15]

Williams K. Curr. Drug Targets, 2001, 2: 285.

[16]

Chenard B L, Bordner J, Butler T W, Chambers L K, Collins M A, De Costa D L, Ducat M F, Dumont M L, Fox C B. Journal of Medicinal Chemistry, 1995, 38: 3138.

[17]

Fischer G, Mutel V, Trube G, Malherbe P, Kew J N, Mohacsi E, Heitz M P, Kemp J A. The Journal of Pharmacology and Experimental Therapeutics, 1997, 283: 1285.

[18]

Stroebel D, Buhl D L, Knafels J D, Chanda P K, Green M, Sciabola S, Mony L, Paoletti P, Pandit J. Mol. Pharmacol., 201, 89: 541.

[19]

Koolen H H, Pral E M, Alfieri S C, Marinho J V, Serain A F, Hernandez-Tasco A J, Andreazza N L, Salvador M J. Phytochemistry, 2017, 134: 106.

[20]

Di Fabio R, Micheli F, Baraldi D, Bertani B, Conti N, Dal Forno G, Feriani A, Donati D, Marchioro C, Messeri T, Missio A, Pasquarello A, Pentassuglia G, Pizzi D A, Provera S, Quaglia A M, Sabbatini F M II Farmaco., 2003, 58: 723.

[21]

Ma C, Du K, Zhao Y, Zhang L K, Hu B C, Cheng M S. Bioorg. Med. Chem., 2018, 26: 5151.

[22]

Zhang L K, Zhao Y, Wang J, Yang D L, Zhao C W, Wang C L, Ma C, Cheng M S. Eur. J. Med. Chem., 2018, 151: 27.

[23]

Zhang L K, Quan J S, Zhao Y, Yang D L, Zhao Q C, Liu P, Cheng M S, Ma C. Eur. J. Med. Chem., 2019, 182: 111654.

[24]

Feng X Y, Jia W Q, Liu X, Jing Z, Liu Y Y, Xu W R, Cheng X C. Comput. Biol. Chem., 2019, 78: 178.

AI Summary AI Mindmap
PDF

144

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/